This paper delves into the therapeutic potential of Acebrophylline in the management of respiratory diseases, specifically focusing on its application in asthma and Chronic Obstructive Pulmonary Disease (COPD). Acebrophylline, a xanthine derivative with bronchodilator and anti-inflammatory properties, has garnered attention for its multifaceted actions in the respiratory system. The objective of this review is to provide comprehensive insights into the pharmacological mechanisms, clinical efficacy, and safety profile of Acebrophylline in the context of asthma and COPD.The review begins by elucidating the pathophysiological basis of asthma and COPD, highlighting the intricate interplay of bronchoconstriction, inflammation, and airway remodelling. Subsequently, the pharmacological attributes of Acebrophylline are explored, shedding light on its dual action as both a bronchodilator and an anti-inflammatory agent. This dual mechanism addresses not only the symptomatic relief but also the underlying inflammatory processes associated with these respiratory conditions.Clinical studies investigating the effectiveness of Acebrophylline in asthma and COPD are meticulously examined, encompassing parameters such as improvement in pulmonary function, reduction in exacerbations, and enhancement of quality of life. Furthermore, the safety profile and tolerability of Acebrophylline are critically assessed, providing valuable insights for clinicians and researchers.
Article Details
Unique Paper ID: 162476
Publication Volume & Issue: Volume 10, Issue 10
Page(s): 396 - 409
Article Preview & Download
Share This Article
Join our RMS
Conference Alert
NCSEM 2024
National Conference on Sustainable Engineering and Management - 2024